Clinical characteristics
| Variable . | Training cohort . | Validation cohort . | P value∗ . |
|---|---|---|---|
| n = 2687 . | n = 1750 . | ||
| Age (%) | |||
| <55 y | 1220 (45.4) | 786 (44.9) | .76 |
| ≥55 y | 1467 (54.6) | 964 (55.1) | |
| Recipient sex (%) | |||
| Male | 1538 (57.2) | 970 (55.4) | .24 |
| Female | 1149 (42.8) | 780 (44.6) | |
| Disease (%) | |||
| AML | 1524 (56.7) | 964 (55.1) | .27 |
| ALL | 403 (15.0) | 291 (16.6) | |
| MDS | 423 (15.7) | 304 (17.4) | |
| MPN | 107 (4.0) | 76 (4.3) | |
| ATL | 230 (8.6) | 115 (6.6) | |
| Refined DRI (%) | |||
| Low | 153 (5.7) | 68 (3.9) | .002 |
| Intermediate | 1277 (47.5) | 905 (51.7) | |
| High | 1257 (46.8) | 777 (44.4) | |
| GVHD prophylaxis (%) | |||
| Tac/MTX | 1056 (39.3) | 680 (38.9) | <.001 |
| Tac/MMF | 965 (35.9) | 780 (44.6) | |
| CsA/MTX | 590 (22.0) | 238 (13.6) | |
| CsA/MMF | 76 (2.8) | 52 (3.0) | |
| HCT-CI (%) | |||
| 0-2 | 2099 (78.1) | 1359 (77.7) | .74 |
| ≥3 | 588 (21.9) | 391 (22.3) | |
| HLA mismatch (%) | |||
| 0-1 | 234 (8.7) | 169 (9.7) | .29 |
| ≥2 | 2453 (91.3) | 1581 (90.3) | |
| PS (%) | |||
| 0-1 | 2425 (90.2) | 1631 (93.2) | .001 |
| 2-4 | 262 (9.8) | 119 (6.8) | |
| Conditioning (%) | |||
| Myeloablative | 1766 (65.7) | 1099 (62.8) | .05 |
| Reduced intensity | 921 (34.3) | 651 (37.2) | |
| CD34+cell doses (%) | |||
| ≥0.82 × 105/kg | 1350 (50.2) | 945 (54.0) | .015 |
| <0.82 × 105/kg | 1337 (49.8) | 805 (46.0) | |
| CFU-GM (%) | |||
| ≥25 × 103/kg | 1361 (50.7) | 853 (48.7) | .22 |
| <25 × 103/kg | 1326 (49.3) | 897 (51.3) | |
| TBI (%) | 2053 (76.4) | 1097 (62.7) | <.001 |
| Variable . | Training cohort . | Validation cohort . | P value∗ . |
|---|---|---|---|
| n = 2687 . | n = 1750 . | ||
| Age (%) | |||
| <55 y | 1220 (45.4) | 786 (44.9) | .76 |
| ≥55 y | 1467 (54.6) | 964 (55.1) | |
| Recipient sex (%) | |||
| Male | 1538 (57.2) | 970 (55.4) | .24 |
| Female | 1149 (42.8) | 780 (44.6) | |
| Disease (%) | |||
| AML | 1524 (56.7) | 964 (55.1) | .27 |
| ALL | 403 (15.0) | 291 (16.6) | |
| MDS | 423 (15.7) | 304 (17.4) | |
| MPN | 107 (4.0) | 76 (4.3) | |
| ATL | 230 (8.6) | 115 (6.6) | |
| Refined DRI (%) | |||
| Low | 153 (5.7) | 68 (3.9) | .002 |
| Intermediate | 1277 (47.5) | 905 (51.7) | |
| High | 1257 (46.8) | 777 (44.4) | |
| GVHD prophylaxis (%) | |||
| Tac/MTX | 1056 (39.3) | 680 (38.9) | <.001 |
| Tac/MMF | 965 (35.9) | 780 (44.6) | |
| CsA/MTX | 590 (22.0) | 238 (13.6) | |
| CsA/MMF | 76 (2.8) | 52 (3.0) | |
| HCT-CI (%) | |||
| 0-2 | 2099 (78.1) | 1359 (77.7) | .74 |
| ≥3 | 588 (21.9) | 391 (22.3) | |
| HLA mismatch (%) | |||
| 0-1 | 234 (8.7) | 169 (9.7) | .29 |
| ≥2 | 2453 (91.3) | 1581 (90.3) | |
| PS (%) | |||
| 0-1 | 2425 (90.2) | 1631 (93.2) | .001 |
| 2-4 | 262 (9.8) | 119 (6.8) | |
| Conditioning (%) | |||
| Myeloablative | 1766 (65.7) | 1099 (62.8) | .05 |
| Reduced intensity | 921 (34.3) | 651 (37.2) | |
| CD34+cell doses (%) | |||
| ≥0.82 × 105/kg | 1350 (50.2) | 945 (54.0) | .015 |
| <0.82 × 105/kg | 1337 (49.8) | 805 (46.0) | |
| CFU-GM (%) | |||
| ≥25 × 103/kg | 1361 (50.7) | 853 (48.7) | .22 |
| <25 × 103/kg | 1326 (49.3) | 897 (51.3) | |
| TBI (%) | 2053 (76.4) | 1097 (62.7) | <.001 |
MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasms.
To calculate the P value, Fisher exact test and χ2 test were used to compare 2 groups and ≥3 groups between the training and validation cohort, respectively.